1. The MERCY trial revealed that continuous infusion of meropenem does not confer a significant advantage over intermittent administration in reducing mortality and preventing new antibiotic-resistant bacteria in patients with either septic shock or sepsis. 2. This randomized control trial provides contrary evidence to previous systematic reviews and meta-analyses that found better outcomes with continuous
There has been a concerted effort over the past 2 decades to improve sepsis outcomes by enhancing recognition of sepsis and decreasing the time to administratio
This randomized clinical trial compares the effect of continuous administration of meropenem vs intermittent administration on a composite outcome of mortality
BOSTON, Nov. 28, 2022 /PRNewswire/ Recent study report released by Data Bridge Market research with titled "Infusion Pump Systems, Accessories and Software Market" (covering USA, Europe,
/PRNewswire/ Recent study report released by Data Bridge Market research with titled "Infusion Pump Systems, Accessories and Software Market" (covering USA,.